Ivana Urošević
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ivana Urošević has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandar Savic
Faculty of Medicine, University of Novi Sad
2 shared publications - Borivoj Sekulic
Clinical Center of Vojvodina, Clinic of Hematology, Novi Sad, Serbia
2 shared publications - Danijela Agic
Faculty of Medicine, Clinic of Hematology, University of Novi Sad, University Clinical Center of Vojvodina, Novi Sad, Serbia
2 shared publications - Dunja Bjelogrlic
Clinic of Hematology, University Clinical Center of Vojvodina, Novi Sad, Serbia
2 shared publications - Ivanka Percic
Faculty of Medicine, Clinic of Hematology, University of Novi Sad, University Clinical Center of Vojvodina, Novi Sad, Serbia
2 shared publications - Jovanka Ilic
Clinic оf Hematology Clinical Center оf Vojvodina Novi Sad Serbia
2 shared publications
Latest Publications
- 20 May 2024
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 65 (10) , 1535-1537
Successful pregnancy outcome in a patient with myelofibrosis receiving ruxolitinib treatment in the first trimester
- 20 May 2024
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 65 (10) , 1535-1537
Successful pregnancy outcome in a patient with myelofibrosis receiving ruxolitinib treatment in the first trimester
- Open Access
- 8 May 2024
- Published by Wiley in Clinical Case Reports
- Vol. 12 (5) , e8900
Eculizumab for paroxysmal nocturnal hemoglobinuria: Two cases of successful pregnancy outcomes
Key Clinical Message: Paroxysmal nocturnal hemoglobinuria is a rare disease with the incidence ranging from 0.08 to 0.57 per 100,000 person‐years. Up to 25% of cases in women are detected during pregnancy. We report two cases of successful pregnancy outcomes in patients treated with eculizumab, pointing out the importance of interdisciplinary approach in these high‐risk pregnancies.
- 8 May 2024
- Published by Wiley in Clinical Case Reports
- Vol. 12 (5) , e8900
Open AccessEculizumab for paroxysmal nocturnal hemoglobinuria: Two cases of successful pregnancy outcomes
Key Clinical Message: Paroxysmal nocturnal hemoglobinuria is a rare disease with the incidence ranging from 0.08 to 0.57 per 100,000 person‐years. Up to 25% of cases in women are detected during pregnancy. We report two cases of successful pregnancy outcomes in patients treated with eculizumab, pointing out the importance of interdisciplinary approach in these high‐risk pregnancies.
- Open Access
- 1 January 2024
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Srpski medicinski casopis Lekarske komore
- Vol. 5 (3) , 437-444
Ferroptosis and its clinical significance
Introduction: Ferroptosis, mentioned as such for the first time in 2012 by Dixon et al., is an iron-dependent type of cell death that occurs in the presence of lipid peroxides. The mechanism of the process and the signaling pathways involved in it differ from the previously known apoptosis, necrosis, and autophagy. An inflammatory reaction also occurs, which further distinguishes this type of cell death from apoptosis. Ferrostatin inhibits this process. Methods: A review of the literature obtained by searching the Medline database was performed, with a special focus on studies concerned with the importance of ferroptosis in clinical medicine, primarily hematology. Results: Iron metabolism in malignant and healthy cells differs. Malignant cells tolerate oxidative stress well and avoid ferroptosis. According to literature data, various tested agents stimulate ferroptosis and thus become possible therapeutic agents. Some genes linked to iron metabolism have shown prognostic significance in patients with diffuse large B-cell lymphoma. Conclusion: The discovery of new mechanisms of cell death and the signaling pathways involved in this process leads to potentially new target therapy. Although promising, these results require validation through further research.
- 1 January 2024
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Srpski medicinski casopis Lekarske komore
- Vol. 5 (3) , 437-444
Open AccessFerroptosis and its clinical significance
Introduction: Ferroptosis, mentioned as such for the first time in 2012 by Dixon et al., is an iron-dependent type of cell death that occurs in the presence of lipid peroxides. The mechanism of the process and the signaling pathways involved in it differ from the previously known apoptosis, necrosis, and autophagy. An inflammatory reaction also occurs, which further distinguishes this type of cell death from apoptosis. Ferrostatin inhibits this process. Methods: A review of the literature obtained by searching the Medline database was performed, with a special focus on studies concerned with the importance of ferroptosis in clinical medicine, primarily hematology. Results: Iron metabolism in malignant and healthy cells differs. Malignant cells tolerate oxidative stress well and avoid ferroptosis. According to literature data, various tested agents stimulate ferroptosis and thus become possible therapeutic agents. Some genes linked to iron metabolism have shown prognostic significance in patients with diffuse large B-cell lymphoma. Conclusion: The discovery of new mechanisms of cell death and the signaling pathways involved in this process leads to potentially new target therapy. Although promising, these results require validation through further research.
- Open Access
- 1 January 2024
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Srpski medicinski casopis Lekarske komore
- Vol. 5 (3) , 331-340
The influence of insulin resistance on therapeutic response in newly diagnosed patients with multiple myeloma
Introduction: According to the results of previous research, it was found that the dysfunction of the insulin-like growth factor (IGF) system, which is the basis of insulin resistance with hyperinsulinemia, acts as a proliferative tumor factor, and its neoplastic potential is also exhibited in multiple myeloma. Study aim: The study aims to determine whether there is an association between insulin resistance in patients newly diagnosed with multiple myeloma (NDMM) and the achieved therapeutic response after induction chemotherapy. Materials and methods: The prospective study included 35 NDMM patients (60% women and 40% men), treated at the Clinical Center of Vojvodina Clinic for Hematology. Glycemia and insulinemia levels were determined after fasting and postprandially, upon which the values of HOMA-IRIf (after fasting) and HOMA-IRIpp (postprandially) were calculated. HOMA-IRI values > 2.2 were the criteria for insulin resistance. The analyses were performed twice - before the initial chemotherapy and after the completion of the treatment. The therapeutic response was evaluated according to the criteria of the Serbian Myeloma Group (SMG) and the International Myeloma Working Group IMWG). Statistical analyses were performed in the SPSS program, Version 22. Results: The average patient age was 63.85 years. In total, 86% of patients responded favorably to the therapy. The average value of HOMA-IRIf before treatment was 1.82 ± 0.79 and it was 1.80 ± 0.72 after therapy. The central median value of HOMA-IRIpp before treatment was 5.46, with an interquartile range of 1.07 - 20.57, and after treatment, it was 5.86 with an interquartile range of 1.22 - 28.22. A significant negative correlation between HOMA-IRIf after applied treatment and achieved therapeutic response was observed, (p = 0.040). Conclusion: Active concomitant therapy of insulin resistance in NDMM could improve the response to applied antimyeloma treatment.
- 1 January 2024
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Srpski medicinski casopis Lekarske komore
- Vol. 5 (3) , 331-340
Open AccessThe influence of insulin resistance on therapeutic response in newly diagnosed patients with multiple myeloma
Introduction: According to the results of previous research, it was found that the dysfunction of the insulin-like growth factor (IGF) system, which is the basis of insulin resistance with hyperinsulinemia, acts as a proliferative tumor factor, and its neoplastic potential is also exhibited in multiple myeloma. Study aim: The study aims to determine whether there is an association between insulin resistance in patients newly diagnosed with multiple myeloma (NDMM) and the achieved therapeutic response after induction chemotherapy. Materials and methods: The prospective study included 35 NDMM patients (60% women and 40% men), treated at the Clinical Center of Vojvodina Clinic for Hematology. Glycemia and insulinemia levels were determined after fasting and postprandially, upon which the values of HOMA-IRIf (after fasting) and HOMA-IRIpp (postprandially) were calculated. HOMA-IRI values > 2.2 were the criteria for insulin resistance. The analyses were performed twice - before the initial chemotherapy and after the completion of the treatment. The therapeutic response was evaluated according to the criteria of the Serbian Myeloma Group (SMG) and the International Myeloma Working Group IMWG). Statistical analyses were performed in the SPSS program, Version 22. Results: The average patient age was 63.85 years. In total, 86% of patients responded favorably to the therapy. The average value of HOMA-IRIf before treatment was 1.82 ± 0.79 and it was 1.80 ± 0.72 after therapy. The central median value of HOMA-IRIpp before treatment was 5.46, with an interquartile range of 1.07 - 20.57, and after treatment, it was 5.86 with an interquartile range of 1.22 - 28.22. A significant negative correlation between HOMA-IRIf after applied treatment and achieved therapeutic response was observed, (p = 0.040). Conclusion: Active concomitant therapy of insulin resistance in NDMM could improve the response to applied antimyeloma treatment.
- 1 January 2024
- Published by National Library of Serbia in Medicinski Pregled
- Vol. 77 (1-2) , 19-24
Cladribine in the treatment of hairy cell leukemia: A single-centre ten-year experience
Introduction. Hairy cell leukemia is a rare, indolent chronic lymphoproliferative disorder characterized by circulating B cells with cytoplasmic projections, pancytopenia, and recurrent infections. This study aims to evaluate the efficacy and safety of cladribine in managing the disease among patients treated at the Clinical Centre of Vojvodina. Material and Methods. This study included 34 patients with immunohistochemically confirmed hairy cell leukemia, treated with cladribine from September 2013 to December 2023. Clinical data were reviewed and analyzed using standard statistical methods. Results. At the time of cladribine administration, the median age was 53; 50% of patients were symptomatic, 65% had pancytopenia, and 62% presented with splenomegaly. After the first cycle, 68.75% of patients achieved a complete hematologic response, and the overall response rate was 100%. The median follow-up period was 51 months. During this period, two patients were diagnosed with non-melanoma skin cancers, one with renal cell carcinoma, and one with both myelodysplastic syndrome and prostate cancer. Additionally, 88% of patients experienced at least one infection, with viral infections being the most frequent complications. Four patients died during the follow-up period, and the 5-year survival rate was 97%. Conclusion. Cladribine is an effective treatment for hairy cell leukemia, demonstrating a good safety profile and potential for long-term remission.
- 1 January 2024
- Published by National Library of Serbia in Medicinski Pregled
- Vol. 77 (1-2) , 19-24
Cladribine in the treatment of hairy cell leukemia: A single-centre ten-year experience
Introduction. Hairy cell leukemia is a rare, indolent chronic lymphoproliferative disorder characterized by circulating B cells with cytoplasmic projections, pancytopenia, and recurrent infections. This study aims to evaluate the efficacy and safety of cladribine in managing the disease among patients treated at the Clinical Centre of Vojvodina. Material and Methods. This study included 34 patients with immunohistochemically confirmed hairy cell leukemia, treated with cladribine from September 2013 to December 2023. Clinical data were reviewed and analyzed using standard statistical methods. Results. At the time of cladribine administration, the median age was 53; 50% of patients were symptomatic, 65% had pancytopenia, and 62% presented with splenomegaly. After the first cycle, 68.75% of patients achieved a complete hematologic response, and the overall response rate was 100%. The median follow-up period was 51 months. During this period, two patients were diagnosed with non-melanoma skin cancers, one with renal cell carcinoma, and one with both myelodysplastic syndrome and prostate cancer. Additionally, 88% of patients experienced at least one infection, with viral infections being the most frequent complications. Four patients died during the follow-up period, and the 5-year survival rate was 97%. Conclusion. Cladribine is an effective treatment for hairy cell leukemia, demonstrating a good safety profile and potential for long-term remission.
- Open Access
Outcomes in COVID-19 Patients with Pneumonia Treated with High-Flow Oxygen Therapy and Baricitinib—Retrospective Single-Center Study
Background. The aim of the study was to assess the effect of baricitinib on 28-day all-cause mortality and the progression of respiratory failure in patients needing transfer to the intensive care unit (ICU) with COVID-19 pneumonia treated with high-flow oxygen therapy. Methods. This retrospective study included hospitalized patients with COVID-19 pneumonia treated with high-flow oxygen non-invasive ventilation receiving standard of care (SOC) or SOC in addition to baricitinib. Data on patients’ characteristics, pro-inflammatory markers, D dimer, and National Early Warning Score 2 (NEWS2) values were collected and compared between groups. The primary endpoint was 28-day all-cause in-hospital mortality and the secondary outcome was transfer to the ICU. Results. The study included 125 patients. The primary outcome was observed in 44.8% of them: 27% in the baricitinib group vs. 62% in the SOC group, p < 0.001. Transfer to the ICU ward was significantly lower in the baricitinib group: 29% vs. 81%, p < 0.001. A significant improvement was observed when the baricitinib group was compared to SOC in procalcitonin, CRP, D-dimer, neutrophil-to-lymphocyte ratio values, and NEWS2. Conclusion. Treatment with baricitinib in addition to SOC was associated with reduced mortality and a lower prevalence of transfer to the ICU in hospitalized patients with COVID-19 pneumonia treated with high-flow oxygen non-invasive therapy.
Open AccessOutcomes in COVID-19 Patients with Pneumonia Treated with High-Flow Oxygen Therapy and Baricitinib—Retrospective Single-Center Study
Background. The aim of the study was to assess the effect of baricitinib on 28-day all-cause mortality and the progression of respiratory failure in patients needing transfer to the intensive care unit (ICU) with COVID-19 pneumonia treated with high-flow oxygen therapy. Methods. This retrospective study included hospitalized patients with COVID-19 pneumonia treated with high-flow oxygen non-invasive ventilation receiving standard of care (SOC) or SOC in addition to baricitinib. Data on patients’ characteristics, pro-inflammatory markers, D dimer, and National Early Warning Score 2 (NEWS2) values were collected and compared between groups. The primary endpoint was 28-day all-cause in-hospital mortality and the secondary outcome was transfer to the ICU. Results. The study included 125 patients. The primary outcome was observed in 44.8% of them: 27% in the baricitinib group vs. 62% in the SOC group, p < 0.001. Transfer to the ICU ward was significantly lower in the baricitinib group: 29% vs. 81%, p < 0.001. A significant improvement was observed when the baricitinib group was compared to SOC in procalcitonin, CRP, D-dimer, neutrophil-to-lymphocyte ratio values, and NEWS2. Conclusion. Treatment with baricitinib in addition to SOC was associated with reduced mortality and a lower prevalence of transfer to the ICU in hospitalized patients with COVID-19 pneumonia treated with high-flow oxygen non-invasive therapy.
- 1 January 2022
- Published by National Library of Serbia in Medicinski Pregled
- Vol. 75 (Suppl. 1) , 121-126
Myeloproliferative neoplasms and pregnancy
Introduction. The Myeloproliferative Neoplasms are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by increased proliferation of the myeloid lineages in the bone marrow. A particular clinical challenge is presented by certain situations in patients with myeloproliferative Neoplasms, which we do not encounter daily. For this reason, in this paper, we will emphasize the approach to overcoming obstacles in patients with Myeloproliferative Neoplasms in specific settings, like pregnancy. Pregnancy with Philadelphia chromosome-negative Myeloproliferative Neoplasms has been reported to be associated with maternal thrombosis, hemorrhage, and placental dysfunction leading to fetal growth restriction or loss. Thrombocytosis, leucocytosis, high level of hematocrit, activation of Platelets, leucocytes, and circulating pro-thrombotic are connected with the pathogenesis of thrombosis in MPNs With survival expectations similar to age-matched controls and excellent response and worldwide access to tyrosine kinase inhibitors, family planning is increasingly important for many patients with chronic myeloid leukemia. All patients were managed by a multidisciplinary team of physicians with obligatory hematological and gynecologistsobstetrician consultations.
- 1 January 2022
- Published by National Library of Serbia in Medicinski Pregled
- Vol. 75 (Suppl. 1) , 121-126
Myeloproliferative neoplasms and pregnancy
Introduction. The Myeloproliferative Neoplasms are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by increased proliferation of the myeloid lineages in the bone marrow. A particular clinical challenge is presented by certain situations in patients with myeloproliferative Neoplasms, which we do not encounter daily. For this reason, in this paper, we will emphasize the approach to overcoming obstacles in patients with Myeloproliferative Neoplasms in specific settings, like pregnancy. Pregnancy with Philadelphia chromosome-negative Myeloproliferative Neoplasms has been reported to be associated with maternal thrombosis, hemorrhage, and placental dysfunction leading to fetal growth restriction or loss. Thrombocytosis, leucocytosis, high level of hematocrit, activation of Platelets, leucocytes, and circulating pro-thrombotic are connected with the pathogenesis of thrombosis in MPNs With survival expectations similar to age-matched controls and excellent response and worldwide access to tyrosine kinase inhibitors, family planning is increasingly important for many patients with chronic myeloid leukemia. All patients were managed by a multidisciplinary team of physicians with obligatory hematological and gynecologistsobstetrician consultations.